Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; TetraMen-T

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 17 Feb 2017 Phase-III clinical trials in Meningococcal group A infections (Prevention, In children) in Puerto Rico (IM) (NCT03077438)
  • 17 Feb 2017 Phase-III clinical trials in Meningococcal group C infections (Prevention, In children) in Puerto Rico (IM) (NCT03077438)
  • 17 Feb 2017 Phase-III clinical trials in Meningococcal group W-135 infections (Prevention, In children) in Puerto Rico (IM) (NCT03077438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top